These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2217458)

  • 1. History and physical examination in prostate cancer. Which information is essential in diagnosis and follow-up?
    Newling DW; Estrada Arras C; Bono A
    Prog Clin Biol Res; 1990; 357():151-6. PubMed ID: 2217458
    [No Abstract]   [Full Text] [Related]  

  • 2. History and physical examination in prostatic cancer--which information is essential in diagnosis and follow up?
    Newling DW; Estrada Arras C; Bono A
    Prog Clin Biol Res; 1988; 269():199-207. PubMed ID: 3393551
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
    Labrie F; Candas B; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M
    Urology; 1996 Feb; 47(2):212-7. PubMed ID: 8607237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality. A case-control study.
    Walsh PC
    J Urol; 2005 Nov; 174(5):1824-5. PubMed ID: 16217296
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prostatic cancer: role of echography in the diagnosis, evaluation and surveillance].
    Fornage B
    Bull Cancer; 1985; 72(5):442-51. PubMed ID: 2416372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial.
    Labrie F; Candas B; Cusan L; Gomez JL; Bélanger A; Brousseau G; Chevrette E; Lévesque J
    Prostate; 2004 May; 59(3):311-8. PubMed ID: 15042607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What clinical information is wanted from measurements of tumor markers in carcinoma of the prostate?
    Andersson L
    Scand J Clin Lab Invest Suppl; 1985; 179():107-14. PubMed ID: 3866303
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
    Tanaka Y; Aoyama H; Momose H; Ono T; Samma S; Tanaka N; Akiyama T; Tani Y; Masuda Y; Matsuki H; Tani M; Tanaka M
    Hinyokika Kiyo; 2001 Jan; 47(1):11-4. PubMed ID: 11235214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inquiry and physical examination (including digital rectal examination) for patients with prostate cancer].
    Ishidoya S
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():228-31. PubMed ID: 22207977
    [No Abstract]   [Full Text] [Related]  

  • 11. The case for prostate cancer screening.
    Andriole GL
    Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dilemmas in managing prostate carcinoma. (Part I): Localized disease.
    Ahmann FR
    Geriatrics; 1985 Jul; 40(7):34-9, 42. PubMed ID: 4007496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of family history of prostate cancer to perceived vulnerability and screening behavior.
    Jacobsen PB; Lamonde LA; Honour M; Kash K; Hudson PB; Pow-Sang J
    Psychooncology; 2004 Feb; 13(2):80-5. PubMed ID: 14872526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
    Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
    Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening: what have we learned?
    Zaragoza MR
    Del Med J; 1999 Jul; 71(7):301-2. PubMed ID: 10457667
    [No Abstract]   [Full Text] [Related]  

  • 16. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE; Altwein JE
    MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for cancer: testicular and prostate cancer.
    Harv Mens Health Watch; 2005 Nov; 10(4):1-6. PubMed ID: 16365955
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.